TITLE

Anti-CDC25B autoantibody predicts poor prognosis in patients with advanced esophageal squamous cell carcinoma

AUTHOR(S)
Jun Dong; Bo-hang Zeng; Li-hua Xu; Jun-ye Wang; Man-Zhi Li; Mu-sheng Zeng; Wan-li Liu
PUB. DATE
January 2010
SOURCE
Journal of Translational Medicine;2010, Vol. 8, p81
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
Background: The oncogene CDC25B phosphatase plays an important role in cancer cell growth. We have recently reported that patients with esophageal squamous cell carcinoma (ESCC) have significantly higher serum levels of CDC25B autoantibodies (CDC25B-Abs) than both healthy individuals and patients with other types of cancer; however, the potential diagnostic or prognostic significance of CDC25B-Abs is not clear. The aim of this study is to evaluate the clinical significance of serum CDC25B-Abs in patients with ESCC. Methods: CDC25B autoantibodies were measured in sera from both 134 patients with primary ESCC and 134 healthy controls using a reverse capture enzyme-linked immunosorbent assay (ELISA) in which anti-CDC25B antibodies bound CDC25B antigen purified from Eca-109 ESCC tumor cells. The clinicopathologic significance of CDC25B serum autoantibodies was compared to that of the tumor markers carcinoembryonic antigen (CEA), squamous cell carcinoma antigen (SCC-Ag) and cytokeratin 19 fragment antigen 21-1(CYFRA21-1). Results: Higher levels of CDC25B autoantibodies were present in sera from patients with ESCC (A450 = 0.917, SD = 0.473) than in sera from healthy control subjects (A450 = 0.378, SD = 0.262, P < 0.001). The area under the receiver operating characteristic (ROC) curve for CDC25B-Abs was 0.870 (95% CI: 0.835-0.920). The sensitivity and specificity of CDC25B-Abs for detection of ESCC were 56.7% and 91.0%, respectively, when CDC25-Abs-positive samples were defined as those with an A450 greater than the cut-off value of 0.725. Relatively few patients tested positive for the tumor markers CEA, SCC-Ag and CYFRA21-1 (13.4%, 17.2%, and 32.1%, respectively). A significantly higher number of patients with ESCC tested positive for a combination of CEA, SCC, CYFRA21-1 and CDC25B-Abs (64.2%) than for a combination of CEA, SCC-Ag and CYFRA21-1 (41.0%, P < 0.001). The concentration of CDC25B autoantibodies in serum was significantly correlated with tumor stage (P < 0.001). Although examination of the total patient pool showed no obvious relationship between CDC25B autoantibodies and overall survival, in the subgroup of patients with stage III-IV tumors, the cumulative five-year survival rate of CDC25B-seropositive patients was 6.7%, while that of CDC25B-seronegative patients was 43.4% (P = 0.001, log-rank). In the N1 subgroup, the cumulative five-year survival rate of CDC25B-seropositive patients was 13.6%, while that of CDC25B-seronegative patients was 54.5% (P = 0.040, log-rank). Conclusions: Detection of serum CDC25B-Abs is superior to detection of the tumor markers CEA, SCC-Ag and CYFRA21-1 for diagnosis of ESCC, and CDC25B-Abs are a potential prognostic serological marker for advanced ESCC.
ACCESSION #
54155959

 

Related Articles

  • Prognostic biomarkers in squamous cell carcinoma of the anus: a systematic review. Lampejo, T.; Kavanagh, D.; Clark, J.; Goldin, R.; Osborn, M.; Ziprin, P.; Cleator, S. // British Journal of Cancer;12/7/2010, Vol. 103 Issue 12, p1858 

    Background: recent decades have seen combination chemoradiotherapy become the standard treatment for anal squamous cell carcinoma (SCC). However, the burden of this disease continues to rise, with only 10% of patients with metastatic disease surviving >2 years. Further insight into...

  • The expression and prognostic significance of Mucin 13 and Mucin 20 in esophageal squamous cell carcinoma. Hui Wang; Luyan Shen; Yao Lin; Qi Shi; Yongbo Yang; Keneng Chen // Journal of Cancer Research & Therapeutics;2015 Sepcial Issue1, Vol. 11, pC74 

    Background: Mucin 13 (MUC13) and Mucin 20 (MUC20) are high molecular weight transmembrane O-linked glycoprotein secreted by epithelium and are widely overexpressed in epithelial tumor cells. Previously, it has been reported that MUC13 and MUC20 were prognostic molecular biomarkers of some...

  • Association of p62/SQSTM1 Excess and Oral Carcinogenesis. Inui, Takuma; Chano, Tokuhiro; Takikita-Suzuki, Mikiko; Nishikawa, Masanori; Yamamoto, Gaku; Okabe, Hidetoshi // PLoS ONE;Sep2013, Vol. 8 Issue 9, p1 

    p62/SQSTM1 (sequestosome1) has never been evaluated in oral epithelium. In order to clarify the role of p62/SQSTM1 in carcinogenesis in oral epithelium, both p62/SQSTM1 and Nrf2 were immunohistochemically evaluated in 54 carcinomas and 14 low grade dysplasias. p62/SQSTM1 knockdowns were also...

  • Cortactin, fascin, and survivin expression associated with clinicopathological parameters in esophageal squamous cell carcinoma. Hsu, K.-F.; Lin, C.-K.; Yu, C.-P.; Tzao, C.; Lee, S.-C.; Lee, Y.-Y.; Tsai, W.-C.; Jin, J.-S. // Diseases of the Esophagus;Aug2009, Vol. 22 Issue 5, p402 

    Cortactin, fascin, and survivin have been documented in several human cancers and play important roles in tumor progression. We collected 57 surgical specimens, including esophageal squamous cell carcinomas (SqCC; 7 well-differentiated, 15 moderately differentiated, and 24 poorly...

  • Special Symposium: Emerging concepts in head and neck cancer diagnostics and therapy.  // Annals of Oncology;Oct2010 Supplement 8, Vol. 21 Issue suppl_8, pviii31 

    No abstract available.

  • WT1, MSH6, GATA5 and PAX5 as epigenetic oral squamous cell carcinoma biomarkers - a short report. Ribeiro, Ilda; Caramelo, Francisco; Marques, Francisco; Domingues, Ana; Mesquita, Margarida; Barroso, Leonor; Prazeres, Hugo; JuliĆ£o, Maria; Baptista, Isabel; Ferreira, Artur; Melo, Joana; Carreira, Isabel // Cellular Oncology (2211-3428);Dec2016, Vol. 39 Issue 6, p573 

    Purpose: Oral squamous cell carcinoma (OSCC) is a frequently occurring aggressive malignancy with a heterogeneous clinical behavior. Based on the paucity of specific early diagnostic and prognostic biomarkers, which hampers the appropriate treatment and, ultimately the development of novel...

  • Levels of Circulating Microparticles in Lung Cancer Patients and Possible Prognostic Value. Chia-Cheng Tseng; Chin-Chou Wang; Huang-Chih Chang; Tzu-Hsien Tsai; Li-Teh Chang; Kuo-Tung Huang; Steve Leu; Chia-Hung Yen; Shih-Feng Liu; Chih-Hung Chen; Cheng-Ta Yang; Hon-Kan Yip; Meng-Chih Lin // Disease Markers;2013, Vol. 35 Issue 5, p301 

    Background. Endothelial-derived microparticles (EDMPs) and platelet-derived microparticles (PDMPs) have been reported to be increasing in various diseases including malignant diseases. Here, we investigated whether these MPs may be useful biomarkers for predicting lung cancer (LC) disease...

  • Overexpression of matriptase correlates with poor prognosis in esophageal squamous cell carcinoma. Ha, Sang; Kim, Ki; Lee, Nam; Kim, Moon; Kim, Seok-Hyung // Virchows Archiv;Jan2014, Vol. 464 Issue 1, p19 

    Matriptase is one of the type II transmembrane serine proteases and is known to be involved in cancer progression. Increased matriptase expression has been reported in a variety of human cancers, and its association with poor prognosis has been highlighted in some cancer types. However, its...

  • Erratum.  // Oncology;Mar2018, Vol. 94 Issue 3, p190 

    A correction to the article ZNF750 Expression Is a Potential Prognostic Biomarker in Esophageal Squamous Cell Carcinoma published in this issue is presented.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics